The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017
暂无分享,去创建一个
Janick Mathys | I. Ustyugova | X. Saelens | Svetlana S. Stegalkina | T. Ysenbaert | M. Vuylsteke | Alexander Botzki | A. Smet | J. P. Catani | Lauren LaRue | T. Strugnell | Guadalupe Cortés-Garcia | João Paulo Portela Catani | Guy Bottu | Janick Mathys | Alexander Botzki | Raul Gomila | John Hamberger | John Catalan | Timothy Farrell | Satyajit Ray | Thorsten U. Vogel | Tod Strugnell
[1] T. Luider,et al. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model , 2022, Journal of virology.
[2] T. Vogel,et al. Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase , 2022, NPJ vaccines.
[3] F. Derosa,et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza , 2021, NPJ vaccines.
[4] N. Wu,et al. Antigenic evolution of human influenza H3N2 neuraminidase is constrained by charge balancing , 2021, bioRxiv.
[5] D. Veesler,et al. Structure-based design of stabilized recombinant influenza neuraminidase tetramers , 2021, Nature Communications.
[6] A. Pekosz,et al. Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding , 2020, PLoS pathogens.
[7] T. Uyeki,et al. Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968. , 2020, American journal of public health.
[8] I. Wilson,et al. Major antigenic site B of human influenza H3N2 viruses has an evolving local fitness landscape , 2020, Nature Communications.
[9] M. Eichelberger,et al. Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] C. D. de Haan,et al. Influenza A Virus Hemagglutinin–Neuraminidase–Receptor Balance: Preserving Virus Motility , 2019, Trends in Microbiology.
[11] L. Gresh,et al. Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] John Huddleston,et al. Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017-2018 influenza season. , 2019, Virus evolution.
[13] M. Eichelberger,et al. The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain , 2019, Nature Microbiology.
[14] L. Gresh,et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection , 2019, Nature Medicine.
[15] M. Kiso,et al. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus , 2019, Nature Microbiology.
[16] John Huddleston,et al. Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017-2018 influenza season , 2019, bioRxiv.
[17] G. Gao,et al. A Sulfonozanamivir Analogue Has Potent Anti‐influenza Virus Activity , 2018, ChemMedChem.
[18] David J. Topham,et al. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.
[19] R. Webby,et al. NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? , 2018, mBio.
[20] M. Eichelberger,et al. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection , 2017, Journal of Virology.
[21] K. Subbarao,et al. Influenza , 2017, The Lancet.
[22] S. Subramaniam,et al. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes , 2017, Nature Microbiology.
[23] Pingan He,et al. Predicting influenza antigenicity from Hemagglutintin sequence data based on a joint random forest method , 2017, Scientific Reports.
[24] M. Eichelberger,et al. Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin , 2017, mBio.
[25] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[26] Nicholas S. Kelley,et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. , 2016, The Lancet. Infectious diseases.
[27] J. Powers,et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.
[28] A. Monto,et al. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.
[29] Brantley R. Herrin,et al. Lamprey VLRB response to influenza virus supports universal rules of immunogenicity and antigenicity , 2015, eLife.
[30] C. Wilke,et al. Geometric Constraints Dominate the Antigenic Evolution of Influenza H3N2 Hemagglutinin , 2015, bioRxiv.
[31] R. Webster,et al. Determination of Neuraminidase Kinetic Constants Using Whole Influenza Virus Preparations and Correction for Spectroscopic Interference by a Fluorogenic Substrate , 2013, PloS one.
[32] Trevor Bedford,et al. Integrating influenza antigenic dynamics with molecular evolution , 2013, eLife.
[33] J. Belmont,et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. , 2013, The Journal of infectious diseases.
[34] G. Gao,et al. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors , 2013, Nature Communications.
[35] R. Cox. Correlates of protection to influenza virus, where do we go from here? , 2013, Human vaccines & immunotherapeutics.
[36] Gavin J. D. Smith,et al. Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. , 2012, The Journal of general virology.
[37] Tong Zhang,et al. Antigenic distance measurements for seasonal influenza vaccine selection. , 2012, Vaccine.
[38] Robert Tibshirani,et al. Hierarchical Clustering With Prototypes via Minimax Linkage , 2011, Journal of the American Statistical Association.
[39] C. Moste,et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. , 2010, Vaccine.
[40] R. Webster,et al. Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.
[41] Cécile Viboud,et al. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. , 2005, The Journal of infectious diseases.
[42] GA Marsh,et al. The role of reverse genetics in the development of vaccines against respiratory viruses , 2005, Expert opinion on biological therapy.
[43] H. Klenk,et al. Neuraminidase Is Important for the Initiation of Influenza Virus Infection in Human Airway Epithelium , 2004, Journal of Virology.
[44] A. Lapedes,et al. Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.
[45] R. Webster,et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.
[46] R. Webster,et al. A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[47] W. Fiers,et al. Recombinant neuraminidase vaccine protects against lethal influenza. , 1996, Vaccine.
[48] G. Air,et al. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. , 1985, Virology.
[49] R. Compans,et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. , 1974, Virology.
[50] A. Monto,et al. Effect of neuraminidase antibody on Hong Kong influenza. , 1973, Lancet.
[51] M. Kaji. [Neuraminidase inhibitor]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.
[52] K. Pardy. DNA transfection. , 1993, Methods in molecular biology.
[53] G. Meiklejohn,et al. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67. , 1969, Bulletin of the World Health Organization.